THRX Insider Trading (Theseus Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $1,528,501.59
Insider Selling (Last 12 Months): $0.00
Theseus Pharmaceuticals Share Price & Price History
Current Price: $7.43
Price Change: ▼ Price Decrease of -0.16 (-2.11%)
As of 05/16/2022 05:00 PM ET
This Options Expert is Giving Everything Away!
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you!
His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
Get your copy today!
Theseus Pharmaceuticals Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/21/2022||Carl L. Gordon||Director||Buy||111,896||$9.97||$1,115,603.12|| |
|1/19/2022||Carl L. Gordon||Director||Buy||11,521||$9.97||$114,864.37|| |
|1/13/2022||Carl L. Gordon||Director||Buy||17,320||$9.43||$163,327.60|| |
|1/11/2022||Carl L. Gordon||Director||Buy||8,500||$10.51||$89,335.00|| |
|12/21/2021||Bradford D. Dahms||CFO||Buy||1,970||$10.15||$19,995.50|| |
|12/21/2021||Timothy P. Clackson||CEO||Buy||2,600||$9.76||$25,376.00|| |
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
Theseus Pharmaceuticals Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/16/2022||California State Teachers Retirement System||4,926||$57K||0.0%||-22.1%||0.013%|
|5/16/2022||Wellington Management Group LLP||293,587||$3.39M||0.0%||-53.0%||0.759%|
|5/16/2022||State Street Corp||182,661||$2.11M||0.0%||+44.1%||0.472%|
|5/11/2022||Bank of New York Mellon Corp||29,379||$0.34M||0.0%||+71.2%||0.076%|
|5/10/2022||TD Asset Management Inc.||67,133||$0.77M||0.0%||+19.4%||0.173%|
|5/5/2022||New York State Common Retirement Fund||9,495||$0.11M||0.0%||+475.1%||0.025%|
|2/19/2022||Wells Fargo & Company MN||6,774||$86K||0.0%||N/A||0.018%|
|2/19/2022||Woodline Partners LP||250,000||$3.17M||0.0%||N/A||0.646%|
|2/16/2022||Deutsche Bank AG||6,993||$89K||0.0%||N/A||0.018%|
|2/16/2022||California State Teachers Retirement System||6,325||$80K||0.0%||N/A||0.016%|
|2/15/2022||Laurion Capital Management LP||205,021||$2.60M||0.0%||N/A||0.530%|
|2/15/2022||Lynx1 Capital Management LP||409,358||$5.19M||4.5%||N/A||1.058%|
|2/15/2022||Adage Capital Partners GP L.L.C.||761,589||$9.66M||0.0%||N/A||1.968%|
|2/14/2022||D. E. Shaw & Co. Inc.||22,136||$0.28M||0.0%||N/A||0.057%|
|2/14/2022||Boxer Capital LLC||892,057||$11.31M||0.4%||N/A||2.305%|
|2/14/2022||Nextech Invest AG||611,310||$7.75M||1.8%||N/A||1.579%|
|2/14/2022||State Street Corp||126,796||$1.61M||0.0%||N/A||0.328%|
|2/14/2022||DAFNA Capital Management LLC||97,500||$1.24M||0.3%||N/A||0.252%|
|2/14/2022||Nuveen Asset Management LLC||17,494||$0.22M||0.0%||N/A||0.045%|
|2/14/2022||Omega Fund Management LLC||711,479||$9.02M||1.3%||N/A||1.838%|
|2/11/2022||Geode Capital Management LLC||192,047||$2.44M||0.0%||N/A||0.496%|
|2/11/2022||Foresite Capital Opportunity Management V LLC||468,820||$5.95M||4.0%||N/A||1.211%|
|2/11/2022||Charles Schwab Investment Management Inc.||30,944||$0.39M||0.0%||N/A||0.080%|
|2/11/2022||Ensign Peak Advisors Inc||250,000||$3.17M||0.0%||N/A||0.646%|
|2/10/2022||JPMorgan Chase & Co.||5,108||$65K||0.0%||N/A||0.013%|
|2/10/2022||TD Asset Management Inc.||56,202||$0.71M||0.0%||N/A||0.145%|
|2/8/2022||Bank of America Corp DE||7,906||$100K||0.0%||N/A||0.020%|
|2/8/2022||Northern Trust Corp||96,884||$1.23M||0.0%||N/A||0.250%|
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Theseus Pharmaceuticals?
Who are the major institutional investors of Theseus Pharmaceuticals?
Which major investors are selling Theseus Pharmaceuticals stock?
Within the previous quarter, THRX stock was sold by these institutional investors:
- Wellington Management Group LLP
- California State Teachers Retirement System
Which major investors are buying Theseus Pharmaceuticals stock?
During the last quarter, THRX stock was purchased by institutional investors including:
- State Street Corp
- Bank of New York Mellon Corp
- BlackRock Inc.
- TD Asset Management Inc.
- New York State Common Retirement Fund
During the last year, these company insiders have bought Theseus Pharmaceuticals stock:
Learn More investors buying Theseus Pharmaceuticals stock.
- Bradford D Dahms (CFO)
- Carl L Gordon (Director)
- Timothy P Clackson (CEO)